Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Antidepressants for the treatment of depression in people with cancer
2015
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
2011 Standout
Breast cancer
2019 Standout
Spontaneous and pronase‐induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines
2012
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
2016
Capecitabine in Addition to Anthracycline- and Taxane-Based Neoadjuvant Treatment in Patients With Primary Breast Cancer: Phase III GeparQuattro Study
2010
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
2021
Cardiac toxicity with anti-HER-2 therapies-what have we learned so far?
2009
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
2012 Standout
Triple-negative breast cancer molecular subtyping and treatment progress
2020 Standout
WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial
2013
Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants
2021 Standout
Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study
2010
Antidepressants in the treatment of depression/depressive symptoms in cancer patients: a systematic review and meta-analysis
2013
The ratio of CD8 + lymphocytes to tumor-infiltrating suppressive FOXP3 + effector regulatory T cells is associated with treatment response in invasive breast cancer
2022 StandoutNobel
Neoadjuvant Therapy in the Treatment of Breast Cancer
2014
Management of Early Invasive Breast Cancer in Very Young Women (<35 years)
2011
Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IX
2011
Early prediction of pathologic response to neoadjuvant therapy in breast cancer: Systematic review of the accuracy of MRI
2012
Breast cancer
2016 Standout
Strategies for minimizing complications of neutropenia: Prophylactic myeloid growth factors or antibiotics
2009
Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review
2012 Standout
Meta-Analysis of Magnetic Resonance Imaging in Detecting Residual Breast Cancer After Neoadjuvant Therapy
2013
Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: Results from an integrated analysis
2008
The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer
2012
TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab
2011
Cancer drug resistance: an evolving paradigm
2013 Standout
Clinical significance of MUC13 in pancreatic ductal adenocarcinoma
2018
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
2011 Standout
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
2016 Standout
Second international consensus guidelines for breast cancer in young women (BCY2)
2016
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
2014 Standout
Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain - results of the LEARN Study
2008
Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients
2015
Effectively nursing patients receiving aromatase inhibitor therapy
2008
ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3)
2017
The landscape of long noncoding RNAs in the human transcriptome
2015 Standout
Tumor-infiltrating CD8+ and FOXP3+ lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy
2014
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Measuring the multifaceted roles of mucin-domain glycoproteins in cancer
2022 StandoutNobel
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Mortality due to cancer treatment delay: systematic review and meta-analysis
2020 Standout
Deep learning in histopathology: the path to the clinic
2021 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Ki67 assessment in breast cancer: an update
2017
Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival
2010
Clinical and prognostic significance of MUC1 expression in patients with esophageal squamous cell carcinoma after radical resection
2018
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2019 Standout
A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study
2012
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
2010
Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression
2014
Docetaxel-related side effects and their management
2009
Triple-negative breast cancer—current status and future directions
2009
Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy
2009
Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America
2014 Standout
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
2016 Standout
Breast Cancer Statistics, 2022
2022 Standout
Aloe‐emodin: A review of its pharmacology, toxicity, and pharmacokinetics
2019 Standout
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
2011 Standout
Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy
2012
Surgical treatment of primary breast cancer in the neoadjuvant setting
2014
Antidepressants for the treatment of depression in people with cancer
2018
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
2009
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
2016 Standout
Immunogenic Cell Death in Cancer Therapy
2012 Standout
Works of K. Mehta being referenced
Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial
2013
Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients—a double-blind, randomized study
2007
Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study
2007
Intensified Neoadjuvant Chemotherapy in Early-Responding Breast Cancer: Phase III Randomized GeparTrio Study
2008
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40—GeparQuattro)
2013
Neoadjuvant Vinorelbine-Capecitabine Versus Docetaxel-Doxorubicin-Cyclophosphamide in Early Nonresponsive Breast Cancer: Phase III Randomized GeparTrio Trial
2008
Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer
2013
Validation of p95 as a predictive marker for trastuzumab-based therapy in primary HER2-positive breast cancer: A translational investigation from the neoadjuvant GeparQuattro study.
2011
Abstract S3-1: Neoadjuvant Chemotherapy in the very young 35 years of age or younger
2012
S5-4: pCR as a Surrogate in HER2−Positive Patients Treated with Trastuzumab.
2011
Neoadjuvant chemotherapy in operable breast cancer with docetaxel, doxorubicin, and cyclophosphamide (TAC) or TAC followed by vinorelbine and capecitabine (NX): Final results and analysis of markers predicting response to treatment
2009
5011 ZORO: Prospective randomized multicenter-study to prevent chemotherapy induced ovarian failure with the GnRH-Agonist Goserelin in young hormone insensitive breast cancer patients receiving anthracycline containing (neo-) adjuvant chemotherapy (GBG 37)
2009
ZORO: A prospective randomized multicenter study to prevent chemotherapy-induced ovarian failure with the GnRH-agonist goserelin in young hormone-insensitive breast cancer patients receiving anthracycline containing (neo-) adjuvant chemotherapy (GBG 37)
2009
Clonidine vs. venlafaxine as treatment for hot flashes in breast cancer patients: A double-blind randomised study
2005
S3-2: Neoadjuvant Chemotherapy Adapted by Interim Response Improves Overall Survival of Primary Breast Cancer Patients – Results of the GeparTrio Trial.
2011
Neoadjuvant treatment of HER2 overexpressing primary breast cancer with trastuzumab given concomitantly to epirubicin/ cyclophosphamide followed by docetaxel ± capecitabine. First analysis of efficacy and safety of the GBG/AGO multicenter intergroup-study “GeparQuattro”
2008